Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Savara (SVRA)

Tipranks - Tipranks - Sat Apr 18, 7:52AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), Savara (SVRA) and Summit Therapeutics (SMMT) with bullish sentiments.

Claim 30% Off TipRanks

Merck & Company (MRK)

Rothschild & Co Redburn analyst Natalya Davies maintained a Buy rating on Merck & Company today and set a price target of $179.00. The company’s shares closed last Thursday at $115.46.

According to TipRanks.com, Davies is ranked #9402 out of 12199 analysts.

Currently, the analyst consensus on Merck & Company is a Moderate Buy with an average price target of $136.37, which is a 16.4% upside from current levels. In a report issued on April 6, J.P. Morgan also maintained a Buy rating on the stock with a $135.00 price target.

See the top stocks recommended by analysts >>

Savara (SVRA)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Savara today and set a price target of $10.00. The company’s shares closed last Thursday at $5.64.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 27.5% and a 56.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Madrigal Pharmaceuticals. ;'>

Savara has an analyst consensus of Strong Buy, with a price target consensus of $11.00, implying an 90.0% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $16.00 price target.

Summit Therapeutics (SMMT)

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Summit Therapeutics, with a price target of $34.00. The company’s shares closed last Thursday at $24.42.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 17.8% and a 57.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Zenas BioPharma, Inc. ;'>

Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.36, which is a 47.5% upside from current levels. In a report issued on April 8, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $45.00 price target.

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).